Richard William Arthur Luke

This inventor holds 13 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Astrazeneca Ab, Syngenta Corporation, Zeneca Limited. Active years: 2001-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard William Arthur Luke. Retrieved from https://idiyas.com/inventor/richard-william-arthur-luke

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 4)

% Patents Active = 84.6

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 3.2

ph-index = 4

Forward Citations = 213(Granted Patents)

Company Filing History:

Years Active: 2001-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12252495 - Protein kinase B inhibitors (2025-03-18),

2. 11760760 - Protein kinase B inhibitors (2023-09-19),

3. 11236095 - Protein kinase B inhibitors (2022-02-01),

4. 10654855 - Protein kinase B inhibitors (2020-05-19),

5. 10059714 - Protein kinase B inhibitors (2018-08-28),

6. 9492453 - Protein kinase B inhibitors (2016-11-15),

7. 8101623 - Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor (2012-01-24),

8. 7476677 - Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of Tie2 (2009-01-13),

9. 7427616 - Condensed pyridines and pyrimidines with tie2 (TEK) activity (2008-09-23),

10. 6541453 - Peptide derivatives (2003-04-01),

11. 6355617 - Peptide derivatives (2002-03-12),

12. 6207644 - Peptide analogues containing a 7-membered lactam ring (2001-03-27),

13. 6184207 - Inhibitors of peptide binding to MHC class II proteins (2001-02-06),

Title: Richard William Arthur Luke: Innovator in Pharmaceutical Compounds

Introduction

Richard William Arthur Luke is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target protein kinase B (PKB). With a total of 13 patents to his name, Luke's work has the potential to impact the treatment of various medical conditions, including cancer.

Latest Patents

Luke's latest patents focus on a novel group of compounds designed as protein kinase B inhibitors. These compounds, represented by Formula (I) or their salts, are aimed at treating or preventing diseases mediated through PKB. The inventions also encompass pharmaceutical compositions that include these compounds, methods for treating diseases associated with PKB, and processes for preparing the compounds of Formula (I). This innovative approach highlights Luke's commitment to advancing medical science and improving patient outcomes.

Career Highlights

Throughout his career, Richard William Arthur Luke has worked with prominent companies in the pharmaceutical industry, including AstraZeneca and Syngenta Corporation. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research and development in the field.

Collaborations

Luke has collaborated with esteemed colleagues such as Zbigniew Stanley Matusiak and Paul David Johnson. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Richard William Arthur Luke stands out as a significant figure in the realm of pharmaceutical inventions. His work on protein kinase B inhibitors showcases his dedication to addressing critical medical challenges. Through his patents and collaborations, Luke continues to make strides in the field, ultimately benefiting patients and the medical community.

Profile summary based on public USPTO records.